ProCE Banner Activity

Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

Conference Coverage
Clinical Thought
The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.

Released: March 10, 2017

Expiration: March 09, 2018

No longer available for credit.

Share

Faculty

Brent A. Neuschwander-Tetri

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie

Gilead

Merck & Co., Inc.

Faculty Disclosure

Primary Author

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Brent A. Neuschwander-Tetri, MD, has disclosed that he has received consulting fees from Allergan, Bristol-Myers Squibb, Boehringer Ingelheim, Conatus, ConSynance, Enanta, Galmed, Janssen, MedImmune/AstraZeneca, Nimbus, Novartis, Pfizer, Receptos, Tobira, and Zafgen.